Clinical characteristics and NUDT15 variants in primary ALL cases
| Case n . | Primary cancer . | Risk group . | Genetic subtypes of primary ALL . | SMN subtype . | Interval, y* . | Cytogenetics of tMDS/AML . | NUDT15 genotype† . | 6-MP dose, mg/m2 . |
|---|---|---|---|---|---|---|---|---|
| 1 | BCP-ALL | HR | — | MDS | 10 | Normal karyotype | WT | 48 |
| 2 | BCP-ALL | IR | — | Bladder cancer | 24 | — | HT | 60 |
| 3 | BCP-ALL | HR | ETV6-RUNX1 | AML | 3 | MLL rearrangement | HT | 32 |
| 4 | BCP-ALL | HR | — | AML | 30 | 45,X,-X, t(8;16;21)(q22;p11.2;q22) | HT | 70 |
| 5 | BCP-ALL | IR | t(1;19) | BCC | 25 | — | WT | 47 |
| 6 | BCP-ALL | HR | — | ES | 9 | — | WT | NA |
| 7 | BCP-ALL | HR | FUS-ERG | AML | 3 | NA | WT | 16.6 |
| 8 | BCP-ALL | SR | — | AML | 8 | MLL rearrangement | WT | 85 |
| 9 | BCP-ALL | SR | — | Neurilemmoma | 12 | — | WT | 68 |
| 10 | T-ALL | SR | — | AML | 2 | Normal karyotype | WT | 115 |
| 11 | BCP-ALL | IR | — | MDS | 4 | 46,XX, add(3)(q26), −7, +mar | HT | 60 |
| 12 | BCP-ALL | HR | — | AML | 4 | Normal karyotype | HT | 38 |
| 13 | BCP-ALL | HR | MLL-AF4 | OS | 8 | — | HT | 37 |
| 14 | BCP-ALL | SR | ETV6-RUNX1 | MDS | 1 | 46,XX t(5;12;17)(q35;p13;q12) | WT | 27 |
| Case n . | Primary cancer . | Risk group . | Genetic subtypes of primary ALL . | SMN subtype . | Interval, y* . | Cytogenetics of tMDS/AML . | NUDT15 genotype† . | 6-MP dose, mg/m2 . |
|---|---|---|---|---|---|---|---|---|
| 1 | BCP-ALL | HR | — | MDS | 10 | Normal karyotype | WT | 48 |
| 2 | BCP-ALL | IR | — | Bladder cancer | 24 | — | HT | 60 |
| 3 | BCP-ALL | HR | ETV6-RUNX1 | AML | 3 | MLL rearrangement | HT | 32 |
| 4 | BCP-ALL | HR | — | AML | 30 | 45,X,-X, t(8;16;21)(q22;p11.2;q22) | HT | 70 |
| 5 | BCP-ALL | IR | t(1;19) | BCC | 25 | — | WT | 47 |
| 6 | BCP-ALL | HR | — | ES | 9 | — | WT | NA |
| 7 | BCP-ALL | HR | FUS-ERG | AML | 3 | NA | WT | 16.6 |
| 8 | BCP-ALL | SR | — | AML | 8 | MLL rearrangement | WT | 85 |
| 9 | BCP-ALL | SR | — | Neurilemmoma | 12 | — | WT | 68 |
| 10 | T-ALL | SR | — | AML | 2 | Normal karyotype | WT | 115 |
| 11 | BCP-ALL | IR | — | MDS | 4 | 46,XX, add(3)(q26), −7, +mar | HT | 60 |
| 12 | BCP-ALL | HR | — | AML | 4 | Normal karyotype | HT | 38 |
| 13 | BCP-ALL | HR | MLL-AF4 | OS | 8 | — | HT | 37 |
| 14 | BCP-ALL | SR | ETV6-RUNX1 | MDS | 1 | 46,XX t(5;12;17)(q35;p13;q12) | WT | 27 |
BCP-ALL, B-cell precursor ALL; BCC, basal cell carcinoma; ES, Ewing sarcoma; HR, high risk; HT, heterozygous type; IR, intermediate risk; MDS, myelodysplastic syndrome; NA, not available; OS, osteosarcoma; SR, standard risk; T-ALL, T-cell precursor ALL; WT, wild type.
Time from primary cancer to SMN.
HT indicates heterozygous for rs116855232.